Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaume Capdevila

Showing results (51-60 of 192) with videos related to

Pageof 20
Sort By:
Therapeutic Advances in Medical Oncology|July 18, 2022
Cabozantinib for the treatment of solid tumors: a systematic reviewPablo Maroto, Camillo Porta, Jaume Capdevila, et al.
Current Oncology Reports|September 19, 2017
Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine TumorsAlberto Carmona-Bayonas, Paula Jiménez-Fonseca, Ana Custodio, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 31, 2025
Merkel cell carcinoma: long-term outcomes after radiotherapy treatmentEnar Recalde Vizcay, Begoña Navalpotro Yagüe, Carla Ferrandiz-Pulido, et al.
Head & Neck|June 5, 2019
Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysisHuy Gia Vuong, An Thi Nhat Ho, Thao T K Tran, et al.
Neuroendocrinology|May 10, 2022
Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine TumorsJaume Capdevila, Michel Ducreux, Rocio García Carbonero, et al.
Cancer Epidemiology|August 16, 2011
Neuroendocrine tumors: a population-based study of incidence and survival in Girona Province, 1994-2004Maria Alsina, Rafael Marcos-Gragera, Jaume Capdevila, et al.
Expert Review of Anticancer Therapy|October 27, 2012
Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinomaMarcia S Brose, Johannes Smit, Jaume Capdevila, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 18, 2022
SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)Jaume Capdevila, Ma Auxiliadora Gómez, Mónica Guillot, et al.
The Oncologist|April 5, 2022
Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand TherapyJaume Capdevila, Enrique Grande, Rocío García-Carbonero, et al.
Clinical Colorectal Cancer|March 19, 2025
A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1)Andrea Cercek, Jean-Baptiste Bachet, Jaume Capdevila, et al.
Pageof 20

Showing results (51-60 of 192) with videos related to

Sort By:
Pageof 20
Therapeutic Advances in Medical Oncology|July 18, 2022
Cabozantinib for the treatment of solid tumors: a systematic reviewPablo Maroto, Camillo Porta, Jaume Capdevila, et al.
Current Oncology Reports|September 19, 2017
Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine TumorsAlberto Carmona-Bayonas, Paula Jiménez-Fonseca, Ana Custodio, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 31, 2025
Merkel cell carcinoma: long-term outcomes after radiotherapy treatmentEnar Recalde Vizcay, Begoña Navalpotro Yagüe, Carla Ferrandiz-Pulido, et al.
Head & Neck|June 5, 2019
Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysisHuy Gia Vuong, An Thi Nhat Ho, Thao T K Tran, et al.
Neuroendocrinology|May 10, 2022
Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine TumorsJaume Capdevila, Michel Ducreux, Rocio García Carbonero, et al.
Cancer Epidemiology|August 16, 2011
Neuroendocrine tumors: a population-based study of incidence and survival in Girona Province, 1994-2004Maria Alsina, Rafael Marcos-Gragera, Jaume Capdevila, et al.
Expert Review of Anticancer Therapy|October 27, 2012
Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinomaMarcia S Brose, Johannes Smit, Jaume Capdevila, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 18, 2022
SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)Jaume Capdevila, Ma Auxiliadora Gómez, Mónica Guillot, et al.
The Oncologist|April 5, 2022
Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand TherapyJaume Capdevila, Enrique Grande, Rocío García-Carbonero, et al.
Clinical Colorectal Cancer|March 19, 2025
A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1)Andrea Cercek, Jean-Baptiste Bachet, Jaume Capdevila, et al.
Pageof 20